AMBOSS funding news – Berlin-based AMBOSS Secures €240 Million in Funding

New Long-term Investors for the Next Decade of Continuous Growth‍

It recently converted to a European stock corporation (SE) and completed a financing round with new primary investors KIRKBI, M&G Investments and Lightrock with participation from existing shareholders.

Benedikt Hochkirchen, Co-Founder and Co-CEO of AMBOSS said, “We choose investors who are committed to our long-term vision and very flexible in the investment duration. Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond, Additional funds will go into further investment in technology and new market segments. Selective acquisitions will also continue to be part of our strategy.”

In 2024, AMBOSS acquired Novaheal, a start-up in the nursing field, and NEJM Knowledge+, a board exam prep product for residents in the US. The recent financing round significantly improves access to capital for AMBOSS.

Read also - EcoDataCenter funding news – EcoDataCenter Secures €450 Million in Funding

Empowering the Next Generation of Health Care Professionals‍

It leads the digital empowerment of physicians by keeping them at the center of the product so that they are tech-enabled to provide the best possible care. Doctors worldwide rely on AMBOSS to continuously combine the latest, trusted medical content with cutting-edge technology.

Dr. Madjid Salimi, Co-Founder and Co-CEO of AMBOSS said, “Technology will not replace health care professionals, but those who embrace it will lead the way,”.

Over 1 million users in more than 180 countries trust AMBOSS for clinical decision-makingand medical education. Every second inpatient treatment in Germany is carried out by a physician supported by AMBOSS. In the US, the majority of medical students use it to successfully prepare for exams, and score higher than with other question banks.

25% of first-year US residents depend on AMBOSS to help them provide excellent patient care. The concept is as simple as it is successful: Medical experts distill relevant medical knowledge, and AI-supported technology places it directly at users’ fingertips.

Trusted Partner for Medical Knowledge, With Over Half a Decade of AI Expertise

Key to this success is strong in-house collaboration between experienced medical experts and technology specialists. Providing precise and actionable recommendations on diagnostics and treatment based on the latest guidelines, AMBOSS is a digital co-pilot for everyday clinical practice, helping to save time and avoid treatment errors.

Responsible use of AI technologies has long played a role in the AMBOSS experience that so many educators and clinicians have valued and trusted for years. It will continue to lead the way through rigorous validation of outcomes and a value-first approach.

Peter Bason, Head of Private Capital at KIRKBI, says, “We have followed AMBOSS’ impressive growth journey, from its successful US expansion to its strong focus on innovation. Its unique platform is becoming a vital tool for both medical students and health care professionals, supporting learning and decision-making at every stage. We are excited to partner with other experienced technology and growth investors to back it’s visionary leadership team in their mission of empowering the next generation of health care professionals worldwide.”

About AMBOSS

Founded in 2012 by a team of physicians, AMBOSS is a global medical knowledge platform that has fundamentally changed the way medical know-how is acquired and utilized at the point of care.

With an emphasis on precise, high-quality content, innovative AI-empowered technology, and a user-centered approach, the company has grown its international team to over 500 employees from more than 50 countries, including scientists, software engineers, and 150+ physicians. AMBOSS has more than 1 million professional users across 180 countries.